A pharmaceutical company acquired a growing startup. The pharmaceutical company has a comprehensive OT stack, while the startup allows employees to install IoT devices without oversight. Both…

Data privacy is a critical consideration due to the sensitive nature of pharmaceutical data (e.g., patient information, intellectual property) and the potential for unmanaged IoT devices to collect or expose personal data, requiring strict controls across combined systems.

Aggregation describes combining data or systems, which is a technical process, but not a primary security consideration for designing combined systems in this high-risk scenario.

Environmental considerations, while important for physical aspects, are not the most pressing security design considerations when integrating vastly different digital security postures and device management philosophies.

Segmentation is essential to isolate the highly critical and sensitive OT stack of the pharmaceutical company from the potentially vulnerable and unmanaged IoT devices of the startup, preventing a breach in one domain from impacting the other.

Safety monitoring is critical for OT, but the immediate security risks posed by unmanaged IoT devices necessitate prioritizing segmentation for containment and data privacy to protect sensitive assets before focusing on operational safety aspects.

While regulations (like HIPAA, GDPR) are highly relevant and drive requirements, 'data privacy' is a more direct and actionable security design consideration that addresses the core regulatory compliance aspect in this context.